

AUGUST 2022

ANNUAL KEYSTONE CONFERENCE MAKES AN IMPACT - INTERVIEW WITH CHRISTIE BEATSON



Do you mind providing us with a brief bio about yourself, your history with the BDC/title/role and your role within this conference itself?

I have been with the Barbara Davis Center for 18 years. I am a Registered Dietitian and Certified Diabetes Care and Education Specialist (CDCES, formally called Certified Diabetes Educator, CDE). I am the clinic manager for the adult clinic. I have been part of the planning committee for several years but this year I was not. I am usually a speaker at the conference speaking on practical topics pertaining to Diabetes Education.

What is the keystone conference?

The ATDC Conference has been an integral part of education and case-based study of upcoming and new diabetes technology for over 25 years. This is an annual course designed to help healthcare providers caring for patients with diabetes, including but not limited to: endocrinologists/diabetes specialists, internists, pediatricians, family physicians, physician assistants, medical residents and fellows, nurse practitioners, nurses, dietitians, social workers, and Certified Diabetes Care and Education Specialists (CDCES)

Attendees had an opportunity to interact with leaders in the field and participate in detailed question and answer sessions with the experts.

The 2022 ATDC Conference provided plenaries on the following topics: Obesity & Diabetes; Automated Insulin Delivery (AID) Systems; Emerging Technologies in Delivery Devices; Technology Innovations; Telehealth & Barriers to Care; Healthcare Costs & Outcomes; Upcoming Treatment Options for Diabetes Management; Diabetes Outcomes; Continuous

Glucose Monitors (CGM); Hypoglycemia Management; and Emerging Topics in the main session.

We also provided plenaries for the Pediatric providers in Prevention or Delaying Onset of T1D; Day-to-Day Pediatric Clinic Challenges; and What to Eat, When to Sleep, and Closing the Loop. For the Adult providers in Challenges in Diabetes Management; Day-to-Day Adult Clinic Challenges; and Patient Experience. Both pediatric and adult split sessions included patient panels (a highlight of the conference). Finally, we hosted 5 keynotes to touch on a wide range of topics.

How many guests attended this conference?

Around 500

What is the general layout of the conference days?

The days started early at 8 am and went to at least 5pm with presentations about every 25 minutes. There are usually several plenary sessions each around a certain general topic and then Q&A after the session.

How has the conference evolved since its inception?

The conference started more than 25 years ago by Peter Chase and was focused on pediatrics. At a certain point (2010 or so) the conference alternated yearly between pediatric and adult. A few years later the conference planning was taken over by Dr. Garg and became a combined pediatric and adult conference focusing on all aspects of Diabetes (both Type 1 and Type 2).

What do you enjoy most about being a part of the planning/execution of this conference?

Seeing what is new in the area of Diabetes and hearing from leaders in the field of Diabetes from all over the world.

*Slides from the conference are available [here](#)
Password: ATDC2022*

1ST DRC SUMMER POSTER SESSION FOSTERS IN-PERSON NETWORKING & DIABETES RESEARCH AMPLIFICATION



This past Friday, July 29, we hosted our first summer poster session. The event overall was full of friendly faces, networking and learning. We had around 90 attendees with 32 posters

presented by students and professionals at all stages..

We would like to formally recognize our 4 awardees for best posters:

David Lorberbaum, PhD - Best Post-Doc

Justin Garrish - Best Grad Student

Quinn Matuschek - Best PRA

Vrushali Patel - Best Undergraduate



Thank you to everyone who helped make this event so successful & sincere thanks to our judges, Drs. Richard Benninger, Jane Reusch and Mia Smith



CONGRATULATIONS DR. LAUREL MESSER FOR BEING FEATURED IN ADA NEWS

**"Automated insulin delivery systems
require manual adjustments for
exercise, high-fat meals"**

Click [Here](#) to read the article

**REGISTER FOR THE NEXT INSTALLMENT OF
THE DIABETES RESEARCH VIRTUAL SEMINAR
SERIES - WEDNESDAY 8/10**



Wednesday, August 10, 2022
11:00 AM PST | 12:00 MST | 1:00 PM CST | 2:00 PM EST

Please register here:

<https://redcap.link/DRC-RandyJ.Seeley08.10.22>



Randy J. Seeley, Ph.D.


*Henry King Ransom Professor of Surgery,
Internal Medicine and Nutritional Sciences
Director, Michigan Nutrition Obesity Research
Center, University of Michigan*

“What bariatric surgery tells us about the role the gut plays in the regulation of metabolism

Bariatric surgery remains the most effective treatment strategy to treat both obesity and type 2 diabetes. This implies that the gut plays a central role in the regulation of overall metabolic function. This makes bariatric surgery not just a clinical tool but also a research tool that helps identify aspects of gut function that regulate a variety of metabolic processes in other organs. This talk will focus on what we know about the molecular underpinnings of bariatric surgery's potent effects with a particular focus on unpublished data around potentially novel gut hormones that regulate responses to surgery, diet and probiotics.

The Diabetes Research Virtual Seminar Series is sponsored by the Diabetes Research Centers and Centers for Diabetes Translational Research whose logos are shown below. Questions, feedback, or suggestions for future speakers? Contact us at: virtual.seminar.series@vumc.org

More information can be found here: <https://www.vumc.org/diabetescenter/virtual-seminar-series>



Click Here to Register for the Virtual Seminar

JOIN US IN PERSON ON THURSDAY 8/11



Barbara Davis Center for Diabetes
UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

***Barbara Davis Center
Faculty Candidate***

***"Pancreatic Islet Function and Dysfunction in
Type 1 Diabetes Pathogenesis"***



Amelia Linnemann, PhD

Associate Professor

*Herman B Wells Center for Pediatric Research
Indiana University School of Medicine*

Thursday, August 11, 2022; 10:00am

Shore Family Auditorium

Host: Lori Sussel, PhD

**JOIN US ON SATURDAY 8/13 FOR THE ANNUAL
BDC RUN FOR THE RING**



TO BENEFIT THE CHILDREN'S DIABETES FOUNDATION

RUN FOR THE RING

SATURDAY, AUGUST 13, 2022

AT THE BARBARA DAVIS CENTER FOR DIABETES
1775 AURORA COURT, AURORA, CO 80045

RUNNING TOWARDS THE "BRASS RING"... THE CURE FOR TYPE 1 DIABETES

REGISTER AT

WWW.RUNSIGNUP.COM/RUNFORTHERING

Registration includes Run for the Ring T-Shirt, timing chip (5K only), race bib, awards ceremony, vendor expo, and breakfast bites

5K RUN/WALK

- \$30 EARLY BIRD*
- START A TEAM
- REGISTRATION: 7AM
- RACE STARTS: 8AM

*Price increases July 1st

KIDS ZONE + FUN RUN

- \$10 EARLY BIRD*
- KIDS ZONE OPENS: 8AM
- FUN RUN BEGINS AFTER 5K AWARDS CEREMONY

ABOUT RUN FOR THE RING

Whether you're a competitive runner or want to enjoy a walk around the beautiful Anschutz Medical Campus, Run for the Ring is an event for everyone. The 5K is a BolderBOULDER qualifying race on a certified course. Kids will love their own track with splash zones, games, and more!

Proceeds support the The Guild of the Children's Diabetes Foundation, whose mission is to fund research, promote diabetes awareness and education, provide scholarships, assist families in need, and sponsor activities for children and their families.

PRESENTED BY



[Click Here to Learn More & Register](#)

OPPORTUNITIES FOR FUNDING

CAIANDTR Pilot & Feasibility Program provides support for early-stage investigators (ESIs) committed to conducting translational research related to diabetes in American Indian and Alaska Native (AI/AN) populations



Investigators may be affiliated with any institution that can receive NIH funds. During this 18-month research and training program, funded investigators will complete and publish a secondary analysis project (Months 1-12) and develop a grant application seeking larger-scale funding for their research efforts (Months 13-18).

Application & Review Timeline

- Call for Applications Opens: July 5, 2022
- **Interest Form Due: September 19, 2022**
- **Complete Application Due: October 3, 2022**
- Response from Reviewers: October 24, 2022
- Written Response to Review: November 7, 2022
- Notification of Award: November 14, 2022
- Project Period: December 1, 2022 – May 31, 2024

Detailed information about this opportunity is available on the [CAIANDTR website](#) and in the [Request for Applications](#).

Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (SEIC-T2D)



This award aims to provide highly specialized research resources to accelerate use of appropriate methods and meaningful and equitable engagement of individuals from and communities of diverse backgrounds and sectors in developing the research priorities and activities that involve them, particularly NIH designated health disparity populations, underserved communities, and those with the highest proportion of diabetes-related morbidity and mortality.

Letter of Intent due September 26, 2022

The SEIC-T2D will provide highly specialized research resources to support field and clinical investigators by fully embedding communities, patients, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T2D will also establish a network consisting of multidisciplinary research investigators, including those from underrepresented groups, with expertise in diabetes mellitus and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T2D prevention and treatment.

If there are any questions, please contact
Dr. Beena Akolkar (akolkarb@extra.niddk.nih.gov) or
Dr. Shavon Artis Dickerson (shavon.artisdickerson@nih.gov).

Notice Number: RFA-DK-22-001
Release Date: June 10, 2022
Application Due Date: October 26, 2022

Expiration Date: October 27, 2022

Click [here](#) to access the full RFA

Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)



National Institute of
Diabetes and Digestive
and Kidney Diseases

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available.

Letter of Intent due September 26, 2022

Notice Number: RFA-DK-21-031

Release Date: July 14, 2022

Application Due Date: October 26, 2022

Expiration Date: October 27, 2022

Click [here](#) to access the full RFA

Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)



National Institute of
Diabetes and Digestive
and Kidney Diseases

This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN)..

Letter of Intent due September 26, 2022

Notice Number: RFA-DK-22-009

Release Date: July 13, 2022

Application Due Date: October 26, 2022

Expiration Date: October 27, 2022

Click [here](#) to access the full RFA

Understanding the Pathophysiology and Clinical Course of

New-Onset Diabetes Following COVID-19 (U01 Clinical Trial Not Allowed) (RFA-DK-22-016)



National Institute of
Diabetes and Digestive
and Kidney Diseases

This Funding Opportunity Announcement invites multiple Program Director/Principal Investigator (multi-PD/PI) applications to conduct a study to establish a longitudinal cohort of individuals who developed diabetes following SARS-CoV-2 infection to understand the pathophysiology and clinical course post-COVID-19 diabetes. The cohort must include children and adults and reflect the geography and demographics of COVID-19 in the U.S. There must be an appropriate comparator population recruited and followed. The goals are to determine the contribution of: 1) specific pathophysiologic pathways; 2) overall health impact of the pandemic; 3) COVID-19 severity, and 4) COVID-19 treatment upon excess new onset diabetes from SARS-CoV-2 infection and response to diabetes therapy.

Letter of Intent due November 20, 2022

Notice Number: RFA-DK-22-016

Release Date: July 13, 2022

Application Due Date: December 20, 2022

Expiration Date: December 21, 2022

Click [here](#) to access the full RFA



Click Here to see all current NIH NIDDK RFAs




University of Colorado
Anschutz Medical Campus

Click here to see current CU INTERNAL Limited Submission Funding Opportunities

Have you considered using a DRC core service?

The DRC contains four biomedical cores that provide services and resources to DRC investigators. These cores are designed to facilitate and broaden CU Denver DRC research by expanding access to shared equipment, enhancing availability and training for emerging technologies, and allowing scientists to have greater access to clinical tissue and data.



Cell and Tissue Analysis

Access to state-of-the-art multi-color confocal microscopy, flow cytometry analysis and cell sorting services, and expert assistance for mass cytometry and ion-beam imaging technologies.


[Learn More about Cell & Tissue Analysis](#)



Clinical Resources

Access to an integrated, campus-wide, research registry enabling informatics-based clinical studies.


[Learn More about our Clinical Resources](#)



Disease Modeling

Access and training in stem cell technologies for in vitro human disease modeling of diabetes & molecular core services.

[Learn More about Disease Modeling](#)



Tissue Procurement & Processing

Access to islet isolation and transplantation services along with access to commonly used cell lines and diabetes-related histology techniques.

[Learn More about Tissue Procurement & Processing](#)

Want us to feature you or a colleague on an upcoming DRC newsletter? Have an important research update?

[Click Here to Submit a Story to the DRC Monthly Newsletter](#)



[Click Here to Follow us on Twitter](#)

Please remember to acknowledge support from the University of Colorado Diabetes Research Center and our associated cores by referencing NIDDK grant #P30-DK116073 in your presentations and publications.

[Click here to visit the DRC Website](#)

[Click Here to Subscribe to this Newsletter](#)

Please contact Lisbel.Woods@CUAnschutz.edu with any questions or feedback about this newsletter

This email was sent to: lisbel.woods@cuanschutz.edu

This email was sent by the University of Colorado

[Manage your email preferences](#) | [Update your contact information](#)

Your CU ID:003f400000mHsmqAAC